Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Aliment Pharmacol Ther. 2018 Jan 29;47(7):1001–1011. doi: 10.1111/apt.14531

Table 5.

Known-Groups Validity: PROs scores by liver disease status

Group A Group B

Measure No cirrhosis
N=456a
Cirrhosis (MELD 6–11)
N=334b
Cirrhosis (MELD≥12)
N=37c
Group A – Group Bd
Mean (SD) Mean (SD) Mean (SD) Mean Difference (95% CI)
HIT-6 scoree 46 (11) 45 (10) 47 (11) −1.5 [−4.9, 2.0]
PROMIS T-scorese
 Fatigue 52 (11) 52 (11) 54 (10) −1.9 [−5.6, 1.7]
 Pain Interference 53 (12) 53 (11) 56 (10) −3.0 [−6.7, 0.7]
 Sleep Disturbance 52 (11) 52 (12) 54 (10) −2.4 [−6.2, 1.4]
 Depression 50 (11) 49 (11) 54 (9) −4.1 [−7.6, −0.6]
 Cognitive Concerns 33 (9) 33 (9) 35 (8) −1.8 [−4.9, 1.2]
 Anger 49 (12) 48 (11) 51 (10) −2.9 [−6.7, 0.8]
 Anxiety 51 (11) 49 (10) 54 (10) −3.5 [−6.9, 0.0]
 Belly Pain 37 (13) 37 (13) 40 (14) −3.3 [−7.7, 1.1]
 Diarrhea 36 (9) 35 (8) 39 (12) −3.8 [−7.7, 0.2]
 Nausea/Vomiting 42 (9) 42 (9) 46 (9) −3.9 [−6.8, −1.0]
HCV-PROf 71 (23) 71 (23) 63 (23) 7.7 [0.0, 15.3]

Note: SD=Standard Deviation; CI=Confidence Interval

a

Sample size ranges from 415–456.

b

Sample size ranges from 312–334.

c

Sample size ranges from 36–37.

d

Group A = No cirrhosis or mild cirrhosis (MELD 6–12), Group B = Advanced Cirrhosis(MELD>12).

e

Higher values indicate more severe symptoms.

f

Higher values indicate higher functional well-being.